Clinical trials · Omaha, NE
Metastatic Brain Tumor clinical trials in Omaha
We’re tracking 14 recruiting metastatic brain tumor studies with a site in or near Omaha — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Omaha
- NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Omaha, NebraskaAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Omaha, NebraskaAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Omaha, NebraskaAges 18 years+ - NCT05636618RecruitingPhase 1/Phase 2
Targeted radiation for certain receptor-positive tumors
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Omaha, NebraskaAges 18–90 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Omaha, NebraskaAges 18 years+ - NCT04222062RecruitingPhase 2
Compare Gliadel implant versus focused brain radiation
This Phase 2 study compares two ways to treat brain metastases: a Gliadel wafer placed during planned surgery versus focused stereotactic radiosurgery. It aims to see which approach works better and is safer for people with a limited number of brain tumor spots.
Omaha, NebraskaAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Omaha, NebraskaAges 18 years+ - NCT07585266RecruitingPhase 3
New drug velzatinib versus imatinib for untreated GIST
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
Omaha, NebraskaAges 18 years+ - NCT01535430Recruiting
Mapping brain function in people with certain brain tumors
This study uses brain “mapping” tests (with MRI and possibly other methods) to identify important brain functions near a tumor. It may help your care team plan a safer surgery by understanding which brain areas do critical tasks.
Omaha, NebraskaAges 19 years+ - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Omaha, NebraskaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Omaha, NebraskaAges 12 years+ - NCT04427384Recruiting
Brain tumor patients treated with GammaTiles registry
This study is a patient registry for people with brain tumors who had surgery to remove as much as safely possible and then had GammaTiles placed. It mainly collects information and follow-up imaging to understand how patients do after the treatment.
Omaha, NebraskaAges Any age - NCT04684368RecruitingPhase 2
New treatment study for children and young adults with NGGCT brain tumors
This Phase 2 study tests a new treatment approach for certain brain tumors called NGGCT in children and young adults. It may help improve outcomes by targeting tumors in specific brain locations and using tumor marker tests to guide care.
Omaha, NebraskaAges 3–29 - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Omaha, NebraskaAges 18 years+
Hear when a new Metastatic Brain Tumor trial opens near Omaha, NE
We’ll email you when one opens near Omaha, NE — at most once a week, no account needed, unsubscribe anytime.
Metastatic Brain Tumor trials in other cities
Where these studies are running near Omaha
Institutions with a site for the recruiting metastatic brain tumor studies listed above.
- University of Nebraska Medical Center · 6 studies
- Nebraska Cancer Specialists · 3 studies
- Alegent Health Bergan Mercy Medical Center
- Alegent Health Immanuel Medical Center
- Alegent Health Lakeside Hospital
- Alegent Health Mercy Hospital
- Children's Hospital and Medical Center of Omaha
- Creighton University Medical Center
What taking part in a metastatic brain tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic brain tumor studies in Nebraska.
Common questions
- Are there metastatic brain tumor clinical trials near Omaha?
- Yes. We're currently tracking 14 recruiting metastatic brain tumor studies with a site near Omaha, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic brain tumor study near Omaha?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Omaha to take part?
- Not necessarily. These studies have a site near Omaha, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic brain tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic brain tumor studies open near Omaha regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.